Acute Ischemic Stroke
Conditions
Keywords
acute ischemia stroke, arterial spin labeling, evaluation
Brief summary
Establish a clinical cohort of acute ischemic stroke patients and find the determinant of the prognosis.
Detailed description
1. Enrollment: screening the candidates based on the inclusion and exclusion criteria, and sign the informed consent. 2. Baseline evaluation: evaluate baseline situation of enrolled candidates. 3. Inpatient view: view and evaluate enrolled candidates respectively at day 1, 3, 7 and 14 after stroke, and record the results. 4. Follow-up: view the candidates at 90 days and one year after stroke onset, and record the results. 5. Data analysis: analyze the results.
Interventions
OTHERroutine therapy of acute ischemia stroke
Routine therapy of acute ischemia stroke based on the guidelines, which generally includes two parts: evaluation and medicine treatment. Evaluation includes peripheral blood test, radiologic examination, electrophysiological examination, ultrasonic examination. Medicine treatment includes drug therapy and rehabilitation.
Sponsors
Ruijin Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
30 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age 30-90, no gender restrictions. 2. Onset of disease ≤7 days. 3. Meet either of the following two conditions: ① Transient ischemic attack (TIA) ② Ischemia stroke (IS) Note: Acute IS diagnosis criteria: sudden and persistent focal or widespread neurological dysfunction, excluding other non-vascular causes of brain dysfunction (such as brain infection, head injury, brain tumor, epilepsy, severe metabolic diseases, or degenerative neurological diseases), confirmed by image as new IS. TIA diagnosis criteria: sudden and reversible focal neurological or retinal ischemic deficit caused by a reversible ischemia, usually lasting less than 24 hours, with no evidence of new IS on imaging, and excluding other non-ischemic causes (such as brain infection, head injury, brain tumor, epilepsy, severe metabolic diseases, or degenerative neurological diseases). 4. Signed informed consent
Exclusion criteria
1. Clear cause of ischemic stroke other than atrial fibrillation. 2. Other ischemic strokes with a clear cause. 3. Presence of non-vascular intracranial disease. 4. Presence of severe systemic diseases. 5. Pregnancy or lactation. 6. Unable to tolerate or cooperate with MRI examination. 7. Unable to comply with follow-up due to geographical or other reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progressively deterioration in acute phase | 7 days after ischemia stroke onset | Number of participants whose SNOB (Standardised nursing observations for stroke) score at 7 days post ischemia stroke ≤ 2 points compared to baseline, and/or NIHSS score at 7 days post ischemia stroke ≥ 2 points compared to baseline are identified as progressively deterioration in acute phase. |
| Bad prognosis of acute ischemia stroke | 90 days after ischemia stroke onset | Number of participants whose mRS (Modified rankin scale) score at 90 days after ischemia \> 2 are identified as bad prognosis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrent vascular episode | 1 year | Including transient ischemia attack, intracranial hemorrhage, ischemia stroke |
| Recurrent artery stenosis | one year after stenting | Degree of artery stenosis at one year after stenting \> 50% |
| Unhealthy status | 1 year | Any dimension in EQ-5D-3L (the generic three-level EuroQol five-dimensional questionnaire) score ≥ 2 |
Countries
China
Contacts
Primary ContactWei Jin, PhD. MD.
Outcome results
None listed